The contribution of omental adipose tissue to adipokine concentrations in patients with the metabolic syndrome

Clinical and Investigative Medicine

Volumn 30, Issue 5, 2007, Pages

  Tarantino, Giovanni ^a   Lobello, Roberto ^a   Scopacasa, Francesco ^a   Contaldo, Franco ^a   Pasanisi, Fabrizio ^a   Cirillo, Michele ^a   De Caterina, Maurizio ^a   Conca, Paolo ^a   Terracciano, Daniela ^a   Gennarelli, Nicola ^a   Ariello, Manuela ^a   Mazzarella, Claudia ^a   Grimaldi, Ernesto ^a   Macchia, Vincenzo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Central obesity; Cortisol; Interleukin 6; Metabolic syndrome; Omental vein blood; Vascular endothelial growth factor

Indexed keywords

ADIPOCYTOKINE; HYDROCORTISONE; INTERLEUKIN 6; VASCULOTROPIN;

ABDOMINAL OBESITY; ADIPOSE TISSUE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; INTRAOPERATIVE PERIOD; MALE; METABOLIC SYNDROME X; OBESITY; OMENTUM; PERIPHERAL VEIN; PRIORITY JOURNAL; SURGICAL PATIENT;

ABDOMINAL FAT; ADIPOKINES; ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; HYDROCORTISONE; INTERLEUKIN-6; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 35948982608     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Palaniappan L, Carnethon MR, Wang Y, et al. Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2004;27:788-93.
2. Maison P, Byrne CD, Hales CN, Day NE, Wareham NJ. Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care 2001;24:1758-63.
3. Lorenzo C, Serrano-Rios M, Martinez-Larrad MT, et al. Central adiposity determines prevalence differences of the metabolic syndrome. Obes Res. 2003;11:1480-7.
4. Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia 2000;43:1498-506.
5. Liu KH, Chan YL, Chan WB, Kong WL, Kong MO, Chan JC. Sonographic measurement of mesenteric fat thickness is a good correlate with cardiovascular risk factors: comparison with subcutaneous and preperitoneal fat thickness, magnetic resonance imaging and anthropometric indexes. Int J Obes Relat Metab Disord. 2003;27:1267-73.
6. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab. 2002;87:3023-8.
7. Ryysy L, Hakkinen AM, Goto T, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000;49:749-58.
8. Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol. 2003;285:906-16.
9. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest. 1995;96:88-98.
10. Vendrell J, Broch M, Vilarrasa N, et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res. 2004;12:962-71.
11. Fenkci S, Rota S, Sabir N, Sermez Y, Guclu A, Akdag B. Relationship of serum interleukin-6 and tumor necrosis factor alpha levels with abdominal fat distribution evaluated by ultrasonography in overweight or obese postmenopausal women. J Investig Med. 2006;54:455-60.
12. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract. 2005;69:29-35.
13. Silha JV, Krsek M, Sucharda P, Murphy LJ. Angiogenic factors are elevated in overweight and obese individual. Int J Obes. 2005;29:1308-14.
14. Miyazawa-Hoshimoto S, Takahashi K, Bujo H, Hashimoto N, Yagui K, Saito Y. Roles of degree of fat deposition and its localization on VEGF expression in adipocytes. Am J Physiol Endocrinol Metab. 2005;288:1128-36.
15. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280:745-51.
16. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998;83:847-50.
17. Hermanowski-Vosatka A, Balkovec JM, Cheng K, et al. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med. 2005;202:517-27.
18. Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC, Grino M. Expression of the mRNA coding for 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab. 2002;87:2701-5.
19. Livingstone DEW, Jones GC, Smith K, et al. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 2000;141:560-3.
20. Goodpaster BH, Thaete FL, Simoneau J-A, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997;46:1579-85.
21. Miyazawa-Hashimoto S, Takashi K, Bujo H, Hashimoto N, Yagui K, Saito Y. Role of degree of fat deposition and its localization on VEGF expression in adipocytes. Am J Physiol Endocrinol Metab. 2005;288:1128-36.
22. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans.Endocrinology 2004;145:2273-82.
23. Oltmanns KM, Dodt B, Schultes B, et al. Cortisol correlates with metabolic disturbances in a population study of type 2 diabetic patients. Eur J Endocrinol. 2006;154:325-31.
24. Masuzaki H, Paterson JM, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294:2166-70.
25. Masuzaki H, Yamamoto H, Kenyon CJ, et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest. 2003;112:83-90.